Astana Biomed Group, an authorized Abcam distributor in Central Asia

PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3] (ab278679)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • PE Rabbit monoclonal [PLCG2Y759-G3] to PLCG 2 (phospho Y759)
  • Suitable for: Flow Cyt
  • Reacts with: Human
  • Conjugation: PE. Ex: 488nm, Em: 575nm

Overview

  • Product name

    PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3]
    See all PLCG 2 primary antibodies

  • Description

    PE Rabbit monoclonal [PLCG2Y759-G3] to PLCG 2 (phospho Y759)

  • Host species

    Rabbit

  • Conjugation

    PE. Ex: 488nm, Em: 575nm

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human PLCG 2 (phospho Y759). The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
    Database link: P16885

    Run BLAST with BLAST the sequence with ExPASy Run BLAST with BLAST the sequence with NCBI

  • Positive control

    • Flow cyt: Ramos cells treated with pervanadate.

Properties

Images

  • Flow Cytometry - PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3] (ab278679)
    Flow Cytometry - PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3] (ab278679)
    Flow cytometric analysis of Ramos cells unstained treated with imatinib (blue) or stained and treated with imatinib (red) or treated with pervanadate (green) usingab278679.
  • PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3] (ab278679)
    PE Anti-PLCG 2 (phospho Y759) antibody [PLCG2Y759-G3] (ab278679)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.